COLL Stock Overview
A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Collegium Pharmaceutical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$34.18 |
| 52 Week High | US$40.95 |
| 52 Week Low | US$20.83 |
| Beta | 1.05 |
| 1 Month Change | -1.61% |
| 3 Month Change | 4.18% |
| 1 Year Change | 48.35% |
| 3 Year Change | 45.82% |
| 5 Year Change | 194.66% |
| Change since IPO | 178.11% |
Recent News & Updates
Collegium Pharmaceutical: Some Positives From Its Quarterly 'Miss'
May 13It Looks Like Shareholders Would Probably Approve Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Package
May 10
Recent updates
Collegium Pharmaceutical: Some Positives From Its Quarterly 'Miss'
May 13It Looks Like Shareholders Would Probably Approve Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Package
May 10Collegium Pharmaceutical Q4: The Beat Goes On
Feb 26These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well
Feb 24There's No Escaping Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Muted Revenues
Jan 05Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly
Nov 12Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?
Aug 09Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?
Mar 10Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?
Oct 18Collegium Pharmaceutical (NASDAQ:COLL) Has A Somewhat Strained Balance Sheet
Jun 24Collegium Pharmaceutical: Oversold And Cheap
Jun 12Collegium Pharmaceutical: Thoughts After Another Strategic Move
Feb 20There Is A Reason Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Undemanding
Feb 15We Think Collegium Pharmaceutical (NASDAQ:COLL) Can Stay On Top Of Its Debt
Oct 30Sizing Up Collegium Pharmaceuticals
Oct 04Shareholder Returns
| COLL | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0.6% | 0.5% | -0.2% |
| 1Y | 48.4% | 17.9% | 28.2% |
Return vs Industry: COLL exceeded the US Pharmaceuticals industry which returned 16.7% over the past year.
Return vs Market: COLL exceeded the US Market which returned 27.7% over the past year.
Price Volatility
| COLL volatility | |
|---|---|
| COLL Average Weekly Movement | 7.1% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: COLL has not had significant price volatility in the past 3 months.
Volatility Over Time: COLL's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 197 | Joe Ciaffoni | www.collegiumpharma.com |
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003.
Collegium Pharmaceutical, Inc. Fundamentals Summary
| COLL fundamental statistics | |
|---|---|
| Market cap | US$1.13b |
| Earnings (TTM) | US$93.29m |
| Revenue (TTM) | US$566.92m |
12.0x
P/E Ratio2.0x
P/S RatioIs COLL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| COLL income statement (TTM) | |
|---|---|
| Revenue | US$566.92m |
| Cost of Revenue | US$78.94m |
| Gross Profit | US$487.98m |
| Other Expenses | US$394.69m |
| Earnings | US$93.29m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.85 |
| Gross Margin | 86.08% |
| Net Profit Margin | 16.46% |
| Debt/Equity Ratio | 280.5% |
How did COLL perform over the long term?
See historical performance and comparison